Table 4.
Serum FST levels in healthy subjects and patients with benign diseases or lung cancer
| Subjects | n | FST mean ± SD (range), pg/mL | LC patients vs BLD patients | BLD/LC patients vs HSs | ||
|---|---|---|---|---|---|---|
| Sensitivity | Specificity | Sensitivity | Specificity | |||
| Healthy subjects | 37 | 760.09 ± 115.65 (570.88–1170.24) | – | – | – | – |
| Benign lung diseases | 22 | 1225.60 ± 323.40 (608.36–1763.76)# | – | – | 68.18% | 97.30% |
| Lung cancer | 91 | 1558.47 ± 380.45 (608.36–2513.85)#** | 45.45% | 90.91% | 94.51% | 97.30% |
| LADC | 33 | 1526.71 ± 305.68 (877.29–2241.09)#** | 45.45% | 90.91% | 96.97% | 97.30% |
| SCC | 29 | 1569.30 ± 411.57 (608.36–2377.47)#** | 44.83% | 90.91% | 93.10% | 97.30% |
| LASC | 2 | 1559.17 ± 136.38 (1422.81–1695.57) | 50% | 90.91% | 100.00% | 97.30% |
| LCLC | 3 | 1877.41 ± 362.26 (1422.81–2309.28) | 66.67% | 90.91% | 100.00% | 97.30% |
| SCLC | 24 | 1549.11 ± 428.23 (608.36–2513.85)#** | 58.33% | 90.91% | 91.67% | 97.30% |
#P < 0.01 compared with healthy group; * P < 0.05, ** P < 0.01, compared with benign disease group